Jove
Visualize
Contact Us

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

259
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
259
IV Infusion to Oral Dosing: Conversion Methods01:28

IV Infusion to Oral Dosing: Conversion Methods

212
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
212
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.6K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

423
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
423

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Blood·2016
Same author

Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance.

PloS one·2013
Same author

No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.

Blood·2013
Same author

Emergency department visits in children with hemophilia.

Pediatric blood & cancer·2012
Same author

VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.

Blood·2011
Same author

A community-based partnership to promote information infrastructure for bleeding disorders.

American journal of preventive medicine·2011
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 3, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

10.8K

A longer acting rFVIII, safe and effective.

Jeanne M Lusher1

  • 1WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE.

Blood
|January 18, 2014
PubMed
Summary
This summary is machine-generated.

A novel recombinant factor VIII (rFVIII) therapy, fused with Fc fragment, shows promise for treating severe hemophilia A. This phase 3 study evaluated its safety and efficacy in a large patient cohort.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K
Author Spotlight: Accelerating Cognitive Impairment Research in Mice Through Stereotaxic Injection and Cost-Effective Dyes
06:48

Author Spotlight: Accelerating Cognitive Impairment Research in Mice Through Stereotaxic Injection and Cost-Effective Dyes

Published on: July 19, 2024

3.0K

Related Experiment Videos

Last Updated: May 3, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

10.8K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K
Author Spotlight: Accelerating Cognitive Impairment Research in Mice Through Stereotaxic Injection and Cost-Effective Dyes
06:48

Author Spotlight: Accelerating Cognitive Impairment Research in Mice Through Stereotaxic Injection and Cost-Effective Dyes

Published on: July 19, 2024

3.0K

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Hemophilia A is a serious bleeding disorder caused by factor VIII deficiency.
  • Current factor VIII replacement therapies require frequent infusions.
  • Fc-fusion technology aims to extend the half-life of therapeutic proteins.

Purpose of the Study:

  • To evaluate the efficacy and safety of a novel Fc-fusion recombinant factor VIII (rFVIII) product.
  • To assess the pharmacokinetic profile and immunogenicity of the rFVIII-Fc fusion protein.
  • To determine the annualized bleeding rate (ABR) in patients receiving prophylactic treatment.

Main Methods:

  • Phase 3, multicenter, open-label study.
  • 165 patients with severe hemophilia A were enrolled.
  • Patients received prophylactic infusions of the rFVIII-Fc product.

Main Results:

  • The study demonstrated effective bleed protection with the rFVIII-Fc fusion protein.
  • Favorable pharmacokinetic parameters were observed, supporting extended dosing intervals.
  • The treatment was generally well-tolerated with a manageable safety profile.

Conclusions:

  • Fc-fusion recombinant factor VIII (rFVIII) represents a potential advancement in hemophilia A management.
  • This novel therapeutic offers a promising option for reducing treatment burden in severe hemophilia A.
  • Further research may explore long-term outcomes and patient-reported benefits.